July 23rd 2024
Data from phase 2 of the SANS-UUI trial are expected to support an application to the FDA for approval of the device in patients with urge urinary incontinence.
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Dr. Werneburg on machine learning and AI’s potential in urology
March 13th 2024"We're really enthusiastic on the overactive bladder end and on the antibiotic resistance end, but much more broadly, [AI is] set up to help us counsel our patients better and help us to improve outcomes for our patients as well," says Glenn T. Werneburg, MD, PhD.
Dr. Tabakin on providing accurate information on third-line OAB treatments
March 4th 2024"I would say that the biggest take-home is that many of our patients are using social media for their health care information, and this may influence their preferences [and] their decision-making," says Alexandra Tabakin, MD.
Navigating Safety Concerns and Adverse Effects in OAB Medications
February 8th 2024In this episode, experts review safety concerns, drug interactions, and common adverse effects (AEs) associated with overactive bladder (OAB) medications. They discuss the impact of AEs like constipation, hypertension, and dry mouth on patient quality of life, strategies for managing these effects, and circumstances warranting a change in treatment. The experts also examine recent clinical evidence linking anti-cholinergic treatments to an increased risk of dementia in older patients, discussing its implications for clinical practice and strategies for urologists to remain vigilant about such safety concerns.
Selection Preferences in Second-Line Therapy Classes for OAB
February 1st 2024Experts explore the clinical benefits and limitations of standard pharmacological options, like anti-muscarinic agents and beta-3 adrenergic agonists, and share their preferences and experiences in selecting and managing treatments for OAB, focusing on the effectiveness and patient-specific considerations in their clinical practice. In this episode, Dr. Kennelly, alongside Drs. Eilber and Benson, discusses the transition to second-line therapies for overactive bladder, focusing on medication classes like anticholinergics and beta-3 agonists. They explore patient-centered considerations such as medication compliance, cost, insurance coverage, and the chronic nature of overactive bladder management, emphasizing individualized treatment based on patient needs and health profiles.
Patient Assessment and Impact of OAB on Patients’ Quality of Life
February 1st 2024Dr. Kennelly, Dr. Kevin Benson, and Dr. Karyn Eilber delve into the significant impact of OAB on patients' quality of life, including its effects on daily activities and mental well-being, and how this burden shapes clinical decisions in the early stages of treatment and selection of appropriate therapeutic options.
Expert: Online resources help improve incontinence, do not reduce clinic visits
January 14th 2024"What we found was that the primary outcome didn't change. Whether you had access to eADVICE or you didn't, most people still wanted to see the specialist at the end of their time, including people who were already dry," says Patrina H. Y. Caldwell, BMed, FRACP, PhD.
Dr. Rickey on the Prevention of Lower Urinary Tract Symptoms Research Consortium
January 10th 2024"PLUS was created to start laying down the foundation for implementing prevention science, and understanding things that helped maintain bladder health [and] things that are risk factors for progression into bladder disease," says Leslie Rickey, MD, MPH.
Dr. Shaw and Dr. Hampson on understanding incontinence’s impact on men
January 6th 2024"I think as urologists that treat incontinence, both Dr. Shaw and I probably have the experience of talking to many men who actually never pursue surgical treatment for their incontinence, but they still want to understand what the options are," says Lindsay A. Hampson, MD, MAS.
Experts urge early exploration of surgical treatments for incontinence in men
January 4th 2024"I think the main [finding] that continues to strike me working with Dr Hampson on this type of work is how different individual incontinence is for the patient who is experiencing it," says Nathan M. Shaw, MD.
Expert on increasing access to overactive bladder medications
December 30th 2023“[We can use] the study to help further those arguments that we should be able to make our clinical decisions based on the patient's presentation, a risk-benefit discussion between patient and physician, and not based on what insurance companies will pay for,” says Michelle E. Van Kuiken, MD.